{
    "info": {
        "nct_id": "NCT03255070",
        "official_title": "A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression",
        "inclusion_criteria": "* Age >18 years\n* Life expectancy >3 months.\n* Female or male subjects whose advanced HER2 expressing cancer has failed standard of care treatments, or for whom such therapy is not acceptable to the subject. Subjects with advanced breast, gastric cancer, or other solid tumor who test positive for HER2 by ASCO/CAP criteria (either IHC or FISH) must have received prior treatment with a trastuzumab containing therapy. Subjects who have been previously treated with pertuzumab, TDM-1, lapatinib, or other available and accessible HER2-directed therapies or investigational therapies are eligible.\n* Disease measurability:\n\n  * Phase 1a: measurable or non-measurable disease per RECIST v 1.1.\n  * Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b).\n* Histopathologic evidence of cancer based upon pathology report.\n* Tumor tissue local laboratory HER2 testing results, adequate tumor sample available for confirmation of HER2 status. Subjects with other types of cancer must have previously tested locally for HER2 status by HER2 IHC or ISH assay.\n\n  * Phase 1a: ISH positive or IHC 3+ advanced cancer (including breast or gastric/esophageal or other solid tumors).\n  * Phase 1b: Cohort 8 advanced breast cancer (IHC 3+ or IHC 2+/ISH); Cohort 9 advanced breast cancer (IHC 2+ / ISH-); Cohort 10 advanced gastric cancer (IHC 3+ or IHC 2+/ISH+) or gastroesophageal junction adenocarcinoma; Cohort 11 other advanced solid tumor cancers with HER2-overexpression (HER2 IHC 3+ or IHC 2+/IHS+); Cohort 12 advanced solid tumor cancers with HER2 activating mutation.\n* Eastern Cooperative Oncology Group Performance Status of 0 to 1.\n* Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the NCI-CTCAE v 4.03 (phase 1a) and v 5.0 ( Phase 1b).\n* Adequate organ functions.\n* Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol.\n* Female subjects must be surgically sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or who commits to use an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 3 months following the last dose of study treatment.\n* Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* History of allergic reactions to any component of ARX788.\n* History of ocular events, or any current ongoing active ocular infections.\n* History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia within 12 months prior to enrollment\n* Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0)\n* History of unstable central nervous system (CNS) metastases\n* Current severe, uncontrolled systemic disease (eg, clinical significant cardiovascular, pulmonary, or metabolic diseases)\n* Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments.\n* Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788.\n* Clinically significant surgical intervention (excluding diagnostic biopsy) within 21 days of the first dose of ARX788\n* Radiotherapy administered less than 21 days prior to the first dose of ARX788, or localized palliative radiotherapy administered less than 7 days prior to the first dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on NCI-CTCAE v 5.0.\n* Pregnancy or breast feeding.\n* Known active HCV, HBV, and/or HIV infection.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Life expectancy >3 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy >3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the NCI-CTCAE v 4.03 (phase 1a) and v 5.0 ( Phase 1b).",
            "criterions": [
                {
                    "exact_snippets": "Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the NCI-CTCAE v 4.03 (phase 1a) and v 5.0 ( Phase 1b)",
                    "criterion": "acute toxicities from any prior therapy, surgery, or radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "NCI-CTCAE grade"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 1a: ISH positive or IHC 3+ advanced cancer (including breast or gastric/esophageal or other solid tumors).",
            "criterions": [
                {
                    "exact_snippets": "ISH positive",
                    "criterion": "ISH status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "IHC 3+",
                    "criterion": "IHC score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "+"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced cancer (including breast or gastric/esophageal or other solid tumors)",
                    "criterion": "cancer type and stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "breast",
                                "gastric",
                                "esophageal",
                                "other solid tumors"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects must be surgically sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or who commits to use an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 3 months following the last dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects must be surgically sterile",
                    "criterion": "female subject surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "sterility_status",
                            "expected_value": "surgically sterile"
                        }
                    ]
                },
                {
                    "exact_snippets": "have a monogamous partner who is surgically sterile",
                    "criterion": "monogamous partner surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "partner_sterility_status",
                            "expected_value": "surgically sterile"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2 years postmenopausal",
                    "criterion": "postmenopausal status",
                    "requirements": [
                        {
                            "requirement_type": "menopausal_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "commits to use an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 3 months following the last dose of study treatment",
                    "criterion": "use of acceptable birth control",
                    "requirements": [
                        {
                            "requirement_type": "birth_control_method",
                            "expected_value": [
                                "intrauterine device",
                                "barrier method with spermicide",
                                "condoms",
                                "hormonal contraceptives",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "duration_of_use",
                            "expected_value": "for the duration of the study and for 3 months following the last dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ functions.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ functions",
                    "criterion": "organ functions",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study.",
            "criterions": [
                {
                    "exact_snippets": "Male subjects must be sterile (biologically or surgically)",
                    "criterion": "male subject sterility",
                    "requirements": [
                        {
                            "requirement_type": "sterility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study",
                    "criterion": "birth control method use",
                    "requirements": [
                        {
                            "requirement_type": "use of reliable birth control method",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female or male subjects whose advanced HER2 expressing cancer has failed standard of care treatments, or for whom such therapy is not acceptable to the subject. Subjects with advanced breast, gastric cancer, or other solid tumor who test positive for HER2 by ASCO/CAP criteria (either IHC or FISH) must have received prior treatment with a trastuzumab containing therapy. Subjects who have been previously treated with pertuzumab, TDM-1, lapatinib, or other available and accessible HER2-directed therapies or investigational therapies are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Female or male subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "female",
                                "male"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced HER2 expressing cancer",
                    "criterion": "HER2 expressing cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "HER2 expression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has failed standard of care treatments, or for whom such therapy is not acceptable to the subject",
                    "criterion": "standard of care treatments",
                    "requirements": [
                        {
                            "requirement_type": "failure or ineligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced breast, gastric cancer, or other solid tumor",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "advanced breast cancer",
                                "advanced gastric cancer",
                                "other advanced solid tumor"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "test positive for HER2 by ASCO/CAP criteria (either IHC or FISH)",
                    "criterion": "HER2 status by ASCO/CAP criteria",
                    "requirements": [
                        {
                            "requirement_type": "HER2 positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "testing method",
                            "expected_value": [
                                "IHC",
                                "FISH"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have received prior treatment with a trastuzumab containing therapy",
                    "criterion": "prior trastuzumab therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with pertuzumab, TDM-1, lapatinib, or other available and accessible HER2-directed therapies or investigational therapies",
                    "criterion": "prior HER2-directed or investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b).",
            "criterions": [
                {
                    "exact_snippets": "measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b)",
                    "criterion": "measurable disease (per RECIST v 1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 1a: measurable or non-measurable disease per RECIST v 1.1.",
            "criterions": [
                {
                    "exact_snippets": "measurable or non-measurable disease per RECIST v 1.1.",
                    "criterion": "disease measurability (per RECIST v 1.1)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable",
                                "non-measurable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histopathologic evidence of cancer based upon pathology report.",
            "criterions": [
                {
                    "exact_snippets": "Histopathologic evidence of cancer based upon pathology report",
                    "criterion": "cancer",
                    "requirements": [
                        {
                            "requirement_type": "histopathologic evidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathology report"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group Performance Status of 0 to 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group Performance Status of 0 to 1",
                    "criterion": "Eastern Cooperative Oncology Group Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 1b: Cohort 8 advanced breast cancer (IHC 3+ or IHC 2+/ISH); Cohort 9 advanced breast cancer (IHC 2+ / ISH-); Cohort 10 advanced gastric cancer (IHC 3+ or IHC 2+/ISH+) or gastroesophageal junction adenocarcinoma; Cohort 11 other advanced solid tumor cancers with HER2-overexpression (HER2 IHC 3+ or IHC 2+/IHS+); Cohort 12 advanced solid tumor cancers with HER2 activating mutation.",
            "criterions": [
                {
                    "exact_snippets": "Cohort 8 advanced breast cancer (IHC 3+ or IHC 2+/ISH)",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": [
                                "IHC 3+",
                                "IHC 2+/ISH"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Cohort 9 advanced breast cancer (IHC 2+ / ISH-)",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "IHC 2+ / ISH-"
                        }
                    ]
                },
                {
                    "exact_snippets": "Cohort 10 advanced gastric cancer (IHC 3+ or IHC 2+/ISH+) or gastroesophageal junction adenocarcinoma",
                    "criterion": "gastric cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": [
                                "IHC 3+",
                                "IHC 2+/ISH+"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Cohort 10 ... gastroesophageal junction adenocarcinoma",
                    "criterion": "gastroesophageal junction adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "Cohort 11 other advanced solid tumor cancers with HER2-overexpression (HER2 IHC 3+ or IHC 2+/IHS+)",
                    "criterion": "solid tumor cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": [
                                "IHC 3+",
                                "IHC 2+/IHS+"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Cohort 12 advanced solid tumor cancers with HER2 activating mutation",
                    "criterion": "solid tumor cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "HER2 mutation",
                            "expected_value": "activating mutation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease measurability:",
            "criterions": [
                {
                    "exact_snippets": "Disease measurability:",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor tissue local laboratory HER2 testing results, adequate tumor sample available for confirmation of HER2 status. Subjects with other types of cancer must have previously tested locally for HER2 status by HER2 IHC or ISH assay.",
            "criterions": [
                {
                    "exact_snippets": "Tumor tissue local laboratory HER2 testing results",
                    "criterion": "tumor tissue HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": "local laboratory HER2 testing results available"
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate tumor sample available for confirmation of HER2 status",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequacy for HER2 confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with other types of cancer must have previously tested locally for HER2 status by HER2 IHC or ISH assay",
                    "criterion": "HER2 status testing in other cancer types",
                    "requirements": [
                        {
                            "requirement_type": "previous local testing",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "testing method",
                            "expected_value": [
                                "HER2 IHC",
                                "ISH assay"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Clinically significant surgical intervention (excluding diagnostic biopsy) within 21 days of the first dose of ARX788",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant surgical intervention (excluding diagnostic biopsy) within 21 days of the first dose of ARX788",
                    "criterion": "clinically significant surgical intervention",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "diagnostic biopsy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788.",
            "criterions": [
                {
                    "exact_snippets": "Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788.",
                    "criterion": "exposure to other investigational or commercial anticancer agents or therapies",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "administered with the intention to treat malignancy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy administered less than 21 days prior to the first dose of ARX788, or localized palliative radiotherapy administered less than 7 days prior to the first dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on NCI-CTCAE v 5.0.",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy administered less than 21 days prior to the first dose of ARX788",
                    "criterion": "radiotherapy administration timing",
                    "requirements": [
                        {
                            "requirement_type": "time since last radiotherapy",
                            "expected_value": {
                                "operator": "<",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "localized palliative radiotherapy administered less than 7 days prior to the first dose of ARX788",
                    "criterion": "localized palliative radiotherapy administration timing",
                    "requirements": [
                        {
                            "requirement_type": "time since last localized palliative radiotherapy",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy-induced toxicity of Grade 2 or greater based on NCI-CTCAE v 5.0",
                    "criterion": "radiotherapy-induced toxicity",
                    "requirements": [
                        {
                            "requirement_type": "severity grade (NCI-CTCAE v 5.0)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergic reactions to any component of ARX788.",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions to any component of ARX788.",
                    "criterion": "allergic reactions to any component of ARX788",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or breast feeding.",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast feeding",
                    "criterion": "breast feeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of unstable central nervous system (CNS) metastases",
            "criterions": [
                {
                    "exact_snippets": "History of unstable central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "history of instability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia within 12 months prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "History of congestive heart failure ... within 12 months prior to enrollment",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris ... within 12 months prior to enrollment",
                    "criterion": "unstable angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable atrial fibrillation ... within 12 months prior to enrollment",
                    "criterion": "unstable atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia within 12 months prior to enrollment",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments.",
            "criterions": [
                {
                    "exact_snippets": "Any uncontrollable intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "controllability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "infection (including subjects with active, symptomatic Covid-19 infections)",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions that could limit study compliance or interfere with assessments",
                    "criterion": "other conditions that could limit study compliance or interfere with assessments",
                    "requirements": [
                        {
                            "requirement_type": "potential to limit study compliance or interfere with assessments",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0)",
            "criterions": [
                {
                    "exact_snippets": "Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0)",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "NCI CTCAE v 5.0 grade"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "NCI CTCAE v 5.0 grade"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of ocular events, or any current ongoing active ocular infections.",
            "criterions": [
                {
                    "exact_snippets": "History of ocular events",
                    "criterion": "ocular events",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any current ongoing active ocular infections",
                    "criterion": "ocular infections",
                    "requirements": [
                        {
                            "requirement_type": "current activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current severe, uncontrolled systemic disease (eg, clinical significant cardiovascular, pulmonary, or metabolic diseases)",
            "criterions": [
                {
                    "exact_snippets": "Current severe, uncontrolled systemic disease",
                    "criterion": "systemic disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical significant cardiovascular ... diseases",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical significant ... pulmonary ... diseases",
                    "criterion": "pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical significant ... metabolic diseases",
                    "criterion": "metabolic disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Willing ... to understand and sign an informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to understand and sign",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing ... to comply with all aspects of the protocol",
                    "criterion": "protocol compliance",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Known active HCV, HBV, and/or HIV infection.",
            "criterions": [
                {
                    "exact_snippets": "Known active HCV",
                    "criterion": "HCV infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active HBV",
                    "criterion": "HBV infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active ... HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}